Core Viewpoint - Nelson Peltz accuses Bob Iger of manipulating Disney's succession plan to maintain his influence within the company, suggesting that Iger set up his successor, Josh D'Amaro, to fail [1][6]. Group 1: Succession and Leadership Dynamics - Peltz claims that Iger chose D'Amaro, the theme parks chief, over Dana Walden to ensure a reason for his continued involvement after stepping down as CEO [2][6]. - D'Amaro is set to take over as CEO next month, while Iger will remain a director and senior adviser until the end of the year [2][11]. - Peltz predicts that Iger will eventually undermine D'Amaro, similar to how he sidelined Bob Chapek, the previous CEO [3][11]. Group 2: Historical Context and Tensions - Iger previously handpicked Chapek as his successor just before the COVID-19 pandemic, which led to significant challenges for Disney [6][9]. - Chapek's tenure was marked by controversies, including clashes with Hollywood talent and issues within Disney's streaming business [9][11]. - Following a disastrous earnings report, Iger was reinstated as CEO in November 2022 after Chapek's abrupt firing [11][12]. Group 3: Peltz's Activism and Proxy Battles - Peltz has been a long-time critic of Disney, building a $500 million stake in late 2022 due to disappointing earnings and losses in the streaming sector [12][13]. - He has engaged in multiple proxy fights against Disney, advocating for a board seat and criticizing the company's leadership and strategic direction [13][14]. - Despite a temporary truce after Iger's return, Peltz resumed his campaign in late 2023, nominating himself and former CFO Jay Rasulo for board positions [13][14].

Core Viewpoint - Jazz Pharmaceuticals has announced the appointment of Renee Gala as the new President and CEO, effective August 11, 2025, succeeding co-founder Bruce Cozadd, who will remain as Chairperson of the Board [1][3]. Company Leadership Transition - The Board of Directors conducted a thorough search for the new CEO, focusing on both internal and external candidates, ultimately selecting Renee Gala due to her exceptional leadership qualities and experience [3]. - Bruce Cozadd, who has been with the company for 22 years, expressed pride in the company's journey and confidence in Gala's ability to lead Jazz into its next growth phase [3][4]. Renee Gala's Background - Renee Gala has over 30 years of experience in finance, strategy, corporate development, and commercialization, having served as CFO and COO at Jazz Pharmaceuticals since 2020 and 2023, respectively [2][4]. - Prior to joining Jazz, Gala held leadership roles at GRAIL Inc. and Theravance Biopharma, showcasing a strong background in the life sciences sector [4][5]. Company Strategy and Vision - Gala emphasized the company's commitment to transforming patient lives through innovative medicines and highlighted the potential for growth within Jazz's market-leading portfolio and promising pipeline [3][6]. - The company aims to continue its focus on corporate development and external innovation to drive value for patients and shareholders [3][6].